Cleveland, OH, USA: Simbionix USA Corporation, the world’s leading provider of medical simulation training and education products for medical professionals and the healthcare industry, is pleased to announce it has been granted a patent in the UK for its innovative PROcedure Rehearsal Studio™.
The PROcedure Rehearsal Studio™ is a first in industry product, allowing clinicians to create a patient specific 3D and 4D anatomical models based on a patient’s imaging data, such as CT, for the purpose of simulating and planning endovascular procedures. The patent was granted on Simbionix’s proprietary technology used in order to simulate an image guided angioplasty procedure based on input from a patient’s 3D medical image, allowing a hands-on planning and rehearsal experience as well as providing physicians with unlimited generation of unique clinical case studies and the ability to better demonstrate a complex clinical procedure to their patients.
Earlier this year, the PROcedure Rehearsal Studio™ software was market cleared in the United States, intended for use as a software interface and image segmentation system for the transfer of imaging data from a medical scanner to an output file. It is also intended as pre-operative software for simulating and evaluating surgical treatment options. Unique to the Simbionix simulation systems, the 3D segmentation model can be exported to the Simbionix ANGIO Mentor™ Simulator practice environment. The results are an advanced method of creating an ever expanding library of modules for training and post-operative debriefing.
“This addition to the company’s comprehensive IP portfolio is evidence to the uniqueness and quality of Simbionix’s products and exceptional development team”, said Simbionix CFO, Mr. Boaz Tal. “Technologically advanced medical education solutions are becoming more accepted and are regularly integrated into medical training programs. The patented PROcedure Rehearsal Studio™ allows for the integration of medical imaging into training, strengthening the link between the clinical and training. Having been granted the patent is an additional sign of recognition for the Simbionix comprehensive line of products, which provide innovative solutions to advance medical performance and ensure patient safety.”